[1] |
Couzin-Frankel J. Breakthrough of the year 2013. cancer immunotherapy[J]. Science,2013,342(6165):1432-1433. doi: 10.1126/science.342.6165.1432
|
[2] |
Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J]. Gastroenterology,2015,148(7):1383-1391. doi: 10.1053/j.gastro.2015.02.055
|
[3] |
Hato T, Goyal L, Greten TF, et al. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions[J]. Hepatology,2014,60(5):1776-1782. doi: 10.1002/hep.v60.5
|
[4] |
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J]. J Exp Med,2000,192(7):1027-1034. doi: 10.1084/jem.192.7.1027
|
[5] |
Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J]. Nat Immunol,2001,2(3):261-268. doi: 10.1038/85330
|
[6] |
Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production[J]. J Immunol,2003,170(3):1257-1266. doi: 10.4049/jimmunol.170.3.1257
|
[7] |
Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity[J]. J Mol Med,2003,81(5):281-287. http://cn.bing.com/academic/profile?id=1870078228&encoded=0&v=paper_preview&mkt=zh-cn
|
[8] |
Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade[J]. Proc Natl Acad Sci U S A,2002,99(19):12293-12297. doi: 10.1073/pnas.192461099
|
[9] |
Sawada Y, Yoshikawa T, Shimomura M, et al. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes[J]. Int J Oncol,2015,46(1):28-36. http://cn.bing.com/academic/profile?id=2038159871&encoded=0&v=paper_preview&mkt=zh-cn
|
[10] |
Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma[J]. Clin Cancer Res,2009,15(3):971-979. doi: 10.1158/1078-0432.CCR-08-1608
|
[11] |
Umemoto Y, Okano S, Matsumoto Y, et al. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy[J]. J Gastroenterol,2015,50(1):65-75. doi: 10.1007/s00535-014-0933-3
|
[12] |
Gehring AJ, Ho ZZ, Tan AT, et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma[J]. Gastroenterology,2009,137(2):682-690. doi: 10.1053/j.gastro.2009.04.045
|
[13] |
Ozkaynak E, Wang L, Goodearl A, et al. Programmed death-1 targeting can promote allograft survival[J].J Immunol,2002,169(11):6546-6553. doi: 10.4049/jimmunol.169.11.6546
|
[14] |
Cao Y, Zhou H, Tao J, et al. Keratinocytes induce local tolerance to skin graft by activating interleukin-10-secreting T cells in the context of costimulation molecule B7-H1[J]. Transplantation,2003,75(8):1390-1396. doi: 10.1097/01.TP.0000061599.24682.EC
|
[15] |
Merck Sharp & Dohme Corporation. Prescribing information for KEYTUDA[EB/OL].[2015-10-05]. http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.
|